News & Events

December 4, 2025

Press release | LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

Upcoming Events

Dec 10

ESMO Immuno-Oncology Congress

Jan 13

JPM Healthcare Conference

Jan 19

BioLogic Summit

December 12, 2025

Interview | Leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimisation

December 7, 2025

Publication | Engineering multispecific antibodies with complete killing selectivity through closed-loop integration of machine learning and high-throughput experimentation

November 13, 2025

Press release | LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025

August 21, 2025

The Pharmaceutical Journal | Designed by AI: the future of antibody drugs

May 29, 2025

Press release | LabGenius Therapeutics Appoints Dr. Angus Sinclair as Chief Scientific Officer

April 22, 2025

Blueprint Series | This AI is Creating Cancer-Killing Molecules

April 14, 2025

Article | Smart Antibodies Will Transform Our Fight Against Solid Tumours

April 1, 2025

Interview | Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

February 13, 2025

Press release | LabGenius Therapeutics Appoints Three Experts to its Team of Scientific Advisors

February 5, 2025

Podcast | ‘Show me the molecule’ – On synthetic biology and cutting through AI hype

January 10, 2025

Press release | LabGenius Appoints Dr. Hannah Seitz as Chief Business Officer

October 22, 2024

Award | LabGenius recognised as one of Bloomberg’s start-ups to watch